Candidate surrogate end points for ESRD after AKI

Morgan E. Grams, Yingying Sang, Josef Coresh, Shoshana H. Ballew, Kunihiro Matsushita, Andrew S. Levey, Tom H. Greene, M. Molnár, Zoltan Szabo, Kamyar Kalantar-Zadeh, Csaba P. Kovesdy

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

AKI, a frequently transient condition, is not accepted by the US Food and Drug Association as an end point for drug registration trials. We assessed whether an intermediate-term change in EGFR after AKI has a sufficiently strong relationship with subsequent ESRD to serve as an alternative end point in trials of AKI prevention and/or treatment. Among 161,185 United States veterans undergoingmajor surgery between 2004 and 2011,we characterized in-hospitalAKI by KidneyDisease ImprovingGlobalOutcomes creatinine criteria and decline in EGFR from prehospitalization to postdischarge time points and quantified associations of these values with ESRD and mortality over a median of 3.8 years. An EGFR decline of30%at 30, 60, and 90 days after discharge occurred in 3.1%, 2.5%, and 2.6%, of survivors without AKI and 15.9%, 12.2%, and 11.7%, of survivors with AKI. For patientswith in-hospital AKI comparedwith those with no AKI and stable EGFR, a 30% decline in EGFR at 30, 60, and 90 days after discharge demonstrated adjusted hazard ratios (95% confidence intervals) of ESRD of 5.60 (4.06 to 7.71), 6.42 (4.76 to 8.65), and 7.27 (5.14 to 10.27), with corresponding estimates for 40% decline in EGFR of 6.98 (5.21 to 9.35), 8.03 (6.11 to 10.56), and 10.95 (8.10 to 14.82). Risks for mortalitywere smaller but consistent in direction. A 30%-40%decline in EGFR after AKI could be a surrogate end point for ESRD in trials of AKI prevention and/or treatment, but additional trial evidence is needed.

Original languageEnglish
Pages (from-to)2851-2859
Number of pages9
JournalJournal of the American Society of Nephrology
Volume27
Issue number9
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Chronic Kidney Failure
Biomarkers
Survivors
Veterans
Pharmaceutical Preparations
Creatinine
Confidence Intervals
Food
Mortality
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Grams, M. E., Sang, Y., Coresh, J., Ballew, S. H., Matsushita, K., Levey, A. S., ... Kovesdy, C. P. (2016). Candidate surrogate end points for ESRD after AKI. Journal of the American Society of Nephrology, 27(9), 2851-2859. https://doi.org/10.1681/ASN.2015070829

Candidate surrogate end points for ESRD after AKI. / Grams, Morgan E.; Sang, Yingying; Coresh, Josef; Ballew, Shoshana H.; Matsushita, Kunihiro; Levey, Andrew S.; Greene, Tom H.; Molnár, M.; Szabo, Zoltan; Kalantar-Zadeh, Kamyar; Kovesdy, Csaba P.

In: Journal of the American Society of Nephrology, Vol. 27, No. 9, 01.01.2016, p. 2851-2859.

Research output: Contribution to journalArticle

Grams, ME, Sang, Y, Coresh, J, Ballew, SH, Matsushita, K, Levey, AS, Greene, TH, Molnár, M, Szabo, Z, Kalantar-Zadeh, K & Kovesdy, CP 2016, 'Candidate surrogate end points for ESRD after AKI', Journal of the American Society of Nephrology, vol. 27, no. 9, pp. 2851-2859. https://doi.org/10.1681/ASN.2015070829
Grams ME, Sang Y, Coresh J, Ballew SH, Matsushita K, Levey AS et al. Candidate surrogate end points for ESRD after AKI. Journal of the American Society of Nephrology. 2016 Jan 1;27(9):2851-2859. https://doi.org/10.1681/ASN.2015070829
Grams, Morgan E. ; Sang, Yingying ; Coresh, Josef ; Ballew, Shoshana H. ; Matsushita, Kunihiro ; Levey, Andrew S. ; Greene, Tom H. ; Molnár, M. ; Szabo, Zoltan ; Kalantar-Zadeh, Kamyar ; Kovesdy, Csaba P. / Candidate surrogate end points for ESRD after AKI. In: Journal of the American Society of Nephrology. 2016 ; Vol. 27, No. 9. pp. 2851-2859.
@article{0f513d9806df49acac9b24e9c6fdce89,
title = "Candidate surrogate end points for ESRD after AKI",
abstract = "AKI, a frequently transient condition, is not accepted by the US Food and Drug Association as an end point for drug registration trials. We assessed whether an intermediate-term change in EGFR after AKI has a sufficiently strong relationship with subsequent ESRD to serve as an alternative end point in trials of AKI prevention and/or treatment. Among 161,185 United States veterans undergoingmajor surgery between 2004 and 2011,we characterized in-hospitalAKI by KidneyDisease ImprovingGlobalOutcomes creatinine criteria and decline in EGFR from prehospitalization to postdischarge time points and quantified associations of these values with ESRD and mortality over a median of 3.8 years. An EGFR decline of30{\%}at 30, 60, and 90 days after discharge occurred in 3.1{\%}, 2.5{\%}, and 2.6{\%}, of survivors without AKI and 15.9{\%}, 12.2{\%}, and 11.7{\%}, of survivors with AKI. For patientswith in-hospital AKI comparedwith those with no AKI and stable EGFR, a 30{\%} decline in EGFR at 30, 60, and 90 days after discharge demonstrated adjusted hazard ratios (95{\%} confidence intervals) of ESRD of 5.60 (4.06 to 7.71), 6.42 (4.76 to 8.65), and 7.27 (5.14 to 10.27), with corresponding estimates for 40{\%} decline in EGFR of 6.98 (5.21 to 9.35), 8.03 (6.11 to 10.56), and 10.95 (8.10 to 14.82). Risks for mortalitywere smaller but consistent in direction. A 30{\%}-40{\%}decline in EGFR after AKI could be a surrogate end point for ESRD in trials of AKI prevention and/or treatment, but additional trial evidence is needed.",
author = "Grams, {Morgan E.} and Yingying Sang and Josef Coresh and Ballew, {Shoshana H.} and Kunihiro Matsushita and Levey, {Andrew S.} and Greene, {Tom H.} and M. Moln{\'a}r and Zoltan Szabo and Kamyar Kalantar-Zadeh and Kovesdy, {Csaba P.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1681/ASN.2015070829",
language = "English",
volume = "27",
pages = "2851--2859",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "9",

}

TY - JOUR

T1 - Candidate surrogate end points for ESRD after AKI

AU - Grams, Morgan E.

AU - Sang, Yingying

AU - Coresh, Josef

AU - Ballew, Shoshana H.

AU - Matsushita, Kunihiro

AU - Levey, Andrew S.

AU - Greene, Tom H.

AU - Molnár, M.

AU - Szabo, Zoltan

AU - Kalantar-Zadeh, Kamyar

AU - Kovesdy, Csaba P.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - AKI, a frequently transient condition, is not accepted by the US Food and Drug Association as an end point for drug registration trials. We assessed whether an intermediate-term change in EGFR after AKI has a sufficiently strong relationship with subsequent ESRD to serve as an alternative end point in trials of AKI prevention and/or treatment. Among 161,185 United States veterans undergoingmajor surgery between 2004 and 2011,we characterized in-hospitalAKI by KidneyDisease ImprovingGlobalOutcomes creatinine criteria and decline in EGFR from prehospitalization to postdischarge time points and quantified associations of these values with ESRD and mortality over a median of 3.8 years. An EGFR decline of30%at 30, 60, and 90 days after discharge occurred in 3.1%, 2.5%, and 2.6%, of survivors without AKI and 15.9%, 12.2%, and 11.7%, of survivors with AKI. For patientswith in-hospital AKI comparedwith those with no AKI and stable EGFR, a 30% decline in EGFR at 30, 60, and 90 days after discharge demonstrated adjusted hazard ratios (95% confidence intervals) of ESRD of 5.60 (4.06 to 7.71), 6.42 (4.76 to 8.65), and 7.27 (5.14 to 10.27), with corresponding estimates for 40% decline in EGFR of 6.98 (5.21 to 9.35), 8.03 (6.11 to 10.56), and 10.95 (8.10 to 14.82). Risks for mortalitywere smaller but consistent in direction. A 30%-40%decline in EGFR after AKI could be a surrogate end point for ESRD in trials of AKI prevention and/or treatment, but additional trial evidence is needed.

AB - AKI, a frequently transient condition, is not accepted by the US Food and Drug Association as an end point for drug registration trials. We assessed whether an intermediate-term change in EGFR after AKI has a sufficiently strong relationship with subsequent ESRD to serve as an alternative end point in trials of AKI prevention and/or treatment. Among 161,185 United States veterans undergoingmajor surgery between 2004 and 2011,we characterized in-hospitalAKI by KidneyDisease ImprovingGlobalOutcomes creatinine criteria and decline in EGFR from prehospitalization to postdischarge time points and quantified associations of these values with ESRD and mortality over a median of 3.8 years. An EGFR decline of30%at 30, 60, and 90 days after discharge occurred in 3.1%, 2.5%, and 2.6%, of survivors without AKI and 15.9%, 12.2%, and 11.7%, of survivors with AKI. For patientswith in-hospital AKI comparedwith those with no AKI and stable EGFR, a 30% decline in EGFR at 30, 60, and 90 days after discharge demonstrated adjusted hazard ratios (95% confidence intervals) of ESRD of 5.60 (4.06 to 7.71), 6.42 (4.76 to 8.65), and 7.27 (5.14 to 10.27), with corresponding estimates for 40% decline in EGFR of 6.98 (5.21 to 9.35), 8.03 (6.11 to 10.56), and 10.95 (8.10 to 14.82). Risks for mortalitywere smaller but consistent in direction. A 30%-40%decline in EGFR after AKI could be a surrogate end point for ESRD in trials of AKI prevention and/or treatment, but additional trial evidence is needed.

UR - http://www.scopus.com/inward/record.url?scp=84964017133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964017133&partnerID=8YFLogxK

U2 - 10.1681/ASN.2015070829

DO - 10.1681/ASN.2015070829

M3 - Article

C2 - 26857682

AN - SCOPUS:84964017133

VL - 27

SP - 2851

EP - 2859

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 9

ER -